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Abstract
Background: Treatment algorithms are considered as key to improve outcomes by enhancing the quality of care. This is the 
first randomized controlled study to evaluate the clinical effect of algorithm-guided treatment in inpatients with major 
depressive disorder.
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Methods: Inpatients, aged 18 to 70  years with major depressive disorder from 10 German psychiatric departments were 
randomized to 5 different treatment arms (from 2000 to 2005), 3 of which were standardized stepwise drug treatment 
algorithms (ALGO). The fourth arm proposed medications and provided less specific recommendations based on a 
computerized documentation and expert system (CDES), the fifth arm received treatment as usual (TAU). ALGO included 
3 different second-step strategies: lithium augmentation (ALGO LA), antidepressant dose-escalation (ALGO DE), and switch 
to a different antidepressant (ALGO SW). Time to remission (21-item Hamilton Depression Rating Scale ≤9) was the primary 
outcome.
Results: Time to remission was significantly shorter for ALGO DE (n = 91) compared with both TAU (n = 84) (HR = 1.67; P = .014) 
and CDES (n = 79) (HR = 1.59; P = .031) and ALGO SW (n = 89) compared with both TAU (HR = 1.64; P = .018) and CDES (HR = 1.56; 
P = .038). For both ALGO LA (n = 86) and ALGO DE, fewer antidepressant medications were needed to achieve remission than 
for CDES or TAU (P < .001). Remission rates at discharge differed across groups; ALGO DE had the highest (89.2%) and TAU the 
lowest rates (66.2%).
Conclusions: A highly structured algorithm-guided treatment is associated with shorter times and fewer medication changes 
to achieve remission with depressed inpatients than treatment as usual or computerized medication choice guidance.
Keywords: treatment algorithms, antidepressants, treatment-resistant depression, medical decision making, German 
Algorithm Project
Introduction
About 30% to 40% of patients with major depressive disor-
der (MDD) do not respond to their first medication trial. More 
than one-half of these nonresponders do not respond to a 
second treatment step (Fava and Rush, 2006; Rush et al., 2006; 
Trivedi et al., 2006b). Even among those who respond, up to 
50% maintain residual symptoms (Frank et al., 1991; Greden, 
2001; Bauer et al., 2013), which increases the risk of relapse 
and chronicity (Paykel et  al., 1995; Bauer et  al., 2013, 2015; 
Bschor et al., 2014).
Treatment algorithms are regarded as key instruments 
to optimize treatment delivery and outcomes. These explicit 
treatment protocols aim at a predefined treatment goal (e.g., 
remission or response). The major procedural elements of 
treatment algorithms are strategies (which treatments to 
use), tactics (how to implement the treatments), treatment 
steps (in what order to implement the different treatments), 
standardized evaluation instruments, and critical decision 
points (CDPs). At CDPs, treatment outcome is assessed and a 
standardized medical decision is derived based on preset “if-
then-rules” (Rush et al., 1998; Adli et al., 2003). A review of 24 
depression disease management programs including treatment 
algorithms revealed a significant improvement in depressive 
symptoms, significantly greater patient satisfaction, and better 
compliance with treatment but also increased healthcare costs 
(Badamgarav et  al., 2003) compared with treatment as usual 
(TAU). However, a large-scale multicenter study to evaluate an 
algorithm-guided treatment of depressed inpatients has not 
yet been performed.
The multi-phase German Algorithm Project (GAP) aims to 
evaluate the efficacy, acceptability, and impact on treatment 
quality of algorithm-guided depression treatment (Adli et  al., 
2003). An open observational 2-year single-center pilot study 
(GAP1) suggested reasonable clinical effectiveness and fea-
sibility of a standardized stepwise drug treatment regimen in 
depressed inpatients (Adli et  al., 2002). GAP2, a single-center 
randomized trial, found algorithm-guided treatment was asso-
ciated with significantly higher remission rates and greater 
treatment quality than TAU (Bauer et al., 2009).
The GAP3 study presented here is a multicenter trial con-
ducted within the German Research Network on Depression that 
included 6 academic and 4 nonacademic psychiatric hospitals. 
GAP3 compared 2 different treatment assistance approaches: 
the standardized stepwise drug treatment algorithm (ALGO) 
and a computerized decision and expert system (CDES) that 
recommends medications based on the patient’s individual 
medication history and regular reminders to change or main-
tain the treatment based on the current response pattern. Both 
approaches, which will be described in detail in the Methods 
section (study design), were compared to TAU in terms of treat-
ment efficacy, treatment quality, tolerability, and acceptance of 
treatment.
We hypothesized that algorithm-guided treatment results in 
superior outcomes compared with TAU. In addition, we aimed 
to compare outcomes of the highly schematic ALGO and the 
partially individualized CDES. Within the 3 ALGO groups, 3 
arms compared different second-step strategies (lithium aug-
mentation; ALGO LA), dose escalation of the initial substance 
(ALGO DE), and switch to another antidepressant (ALGO SW) 
in nonresponders to an initial medium-dose antidepressant 
monotherapy.
Significance Statement
Providing algorithm-guided antidepressive treatments is considered an important strategy to optimize treatment delivery and 
avoid or overcome treatment-resistant courses of major depressive disorder (MDD), still a major challenge in the treatment of 
depression. The clinical benefit of algorithms in the treatment of inpatients with MDD had not been investigated in a large-scale, 
randomized, controlled trial before. The aim of the German Algorithm Project therefore was to evaluate the effects of treatment 
algorithms in the care of inpatients with MDD. Results show that a stepwise treatment regimen with critical decision points at 
the end of each treatment step based on standardized measurements of response and an algorithm-guided decision-making 
process increases the chance of achieving remission and optimizes prescription behaviors for antidepressants.
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Methods
This randomized controlled parallel-designed clinical multi-
center GAP3 trial, conducted between 2000 and 2005, was part 
of a naturalistic study (Seemuller et al., 2010) that described the 
outcomes of all depressed inpatients from admission to dis-
charge with the primary diagnosis of a major depressive episode 
according to ICD-10.
Participants
Adult inpatients (aged 18–70 years) with a current major depres-
sive episode (unipolar, with or without psychotic symptoms, but 
not with bipolar depression) and a 21-item Hamilton Depression 
Rating Scale (HAMD-21) (Hamilton, 1960; Williams, 1988) score 
of ≧15 were study eligible. Exclusion criteria were: pregnancy or 
breastfeeding, preexisting psychotropic medication treatment 
that could not be discontinued, and specific medical conditions 
that presented a limitation for any possible study treatment 
(e.g., renal insufficiency as a limitation for lithium). All patients 
admitted to each participating center were systematically 
assessed for eligibility. Each local ethical committee approved 
and monitored the study. All study participants provided written 
informed consent.
Study Design
Figure 1 summarizes the study design. Upon enrollment, 
patients were equally randomized into 5 treatment groups. 
Within the 3 ALGO groups, all participants began with any 1 of 
4 different antidepressants chosen to represent common phar-
macological classes: (selective-serotonin-reuptake-inhibitor) 
sertraline; (serotonin-noradrenalin-reuptake-inhibitor) ven-
lafaxine; (selective-nor-adrenaline-reuptake-inhibitor) rebox-
etine; (tricyclic antidepressant) amitriptyline. The second steps 
represent 3 different common next step strategies (ALGO LA, 
ALDO DE, or ALGO SW) that could be taken when nonresponse 
to the first step (4-week medium dose antidepressant mono-
therapy) occurred. For this report, we label each pathway by the 
second step itself. The subsequent steps in ALGO also differed 
as depicted in Figure 1. ALGO mandated further strategies based 
on prior responses to each step. For ALGO LA, serum levels were 
assessed weekly (target dose 0.6–0.8 mmol/L) (Bauer et al., 2013). 
As part of the ALGO procedure, the HAMD-21 score difference 
Figure 1. Overview of the study design. ALGO, standardized stepwise drug treatment algorithm; ALGO DE, ALGO pathway with dose escalation; ALGO LA, ALGO path-
way with lithium augmentation; ALGO SW, ALGO pathway with antidepressant switch; CDES, computerized documentation and expert system; ECT, electroconvulsive 
therapy; MAO-inhibitor, monoamine oxidase inhibitor; TAU, treatment as usual. The indicated doses refer to doses per day.
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between the beginning and the end of each 4-week step was 
used to ascribe remission, partial response, or nonresponse 
as the outcome. Remission was declared with a HAMD-21 ≤9. 
Remission was to be confirmed in a retest after 2 weeks. If recur-
rence was observed, the patient either received a 2-week pro-
longation of the specific treatment step (if HAMD-21 = 10–14) or 
directly moved to the next step (if HAMD-21 was ≥15).
If partial response occurred (defined as a score reduction 
of >8 or >30% without achieving remission), a 2-week prolon-
gation of the current treatment step was allowed (only once 
per step). Nonresponse was defined as not meeting remission 
or partial response criteria. These patients moved to the next 
treatment step.
CDES used individual patients’ information, prior treat-
ment history, risk factors, and responses to the current treat-
ment with a probability matrix to generate suggestions based 
on a clinical data pool derived from treatment courses of 650 
patients with MDD (Laakman et  al., 1995; Faltermaier-Temizel 
et al., 1997). The software calculated the probability of an indi-
vidual patient’s response every 2 weeks based on the HAMD-
21 score. If response was determined to be likely, the system 
recommended maintaining the strategy. In cases of unlikely 
responses, the software recommended changing the current 
strategy but in a more general way (e.g., “consider augmentation 
or switch to another compound”). In addition, CDES provided 
an overview of past treatments and listed previous treatments 
associated with response or nonresponse or side effects in each 
patient (for additional information please see Appendix 1). The 
fifth group received TAU.
Measures
A systematic interview (Cording, 1995) captured baseline clinical 
and socio-demographic features of the sample. Clinical diagno-
ses were confirmed with the Structured Clinical Interview for 
DSM-IV (Wittchen, 1997). The Structured Clinical Interview-II 
assessed comorbid personality disorders (Wittchen, 1997).
In all 5 groups, treatment outcome was assessed every 2 
weeks (±3 days) by nonmasked research staff who were unin-
volved in treatment. The primary outcome based on the HAMD-
21 was time to remission (HAMD-21 ≤9).
Secondary outcomes included dropout rates and treatment 
process parameters for each group (e.g., number of strategy 
changes, ascribed when a new medication was added or discon-
tinued; total number of psychotropic medications, number of 
different pharmacological drug classes).
Medication doses were calculated as defined drug doses, 
the assumed average maintenance dose per day for a medi-
cation used for its main indication in adults (WHO, 2003). We 
used the recommendations in the Antidepressant Treatment 
History Form to define adequate doses of antidepressants 
(Sackeim, 2001) based on the minimal dosage at which rand-
omized controlled trials have shown the agent to be effective in 
major depression. Dropout reasons were withdrawal of consent, 
discharge or transfer to another hospital (patient’s or doctor’s 
choice) before remission or final rating, protocol violations, side 
effects, or suicide (supplementary Table  1). Patients from TAU 
were rated as dropouts in case of withdrawal of consent, prema-
ture discharge, or suicide.
Concomitant Treatments
Modest concomitant medication restrictions were placed on 
patients in ALGO. Lorazepam and non-benzodiazepine hyp-
notics (zopiclone and zolpidem) were permitted for agitation, 
anxiety, or sleeping problems. In psychotic depression, risperi-
done (up to 4 mg/d) or olanzapine (up to 15 mg/d) were allowed 
as co-medication.
Randomization and Masking
Randomization was performed in blocks of 10, separately for 
each study site, and random figures were generated using www.
randomizer.org. Study staff and patients were masked to the 
randomization code until inclusion assessment was finished. 
Thereafter, patients, physicians, and outcome assessors were 
not blinded to the treatment allocation.
Statistical Analysis
The sample size estimate of 450 participants was based on the 
primary outcome variable: time to remission. Assumptions 
were a variance of 4 weeks and a mean difference of 2 weeks 
between groups was used a priori to define clinical relevance. 
This is equivalent to an effect size of d = 0.50, and power would 
be 0.80. To account for dropouts, 90 patients had to be enrolled 
per study group.
SPSS (Statistical Package for Social Science) version 18.0 was 
used for statistical operations. Calculations were performed with 
SAS version 6.12 for Windows NT and UnifyPow. Differences in 
baseline or treatment characteristics between the groups (ALGO 
groups, CDES, and TAU) were assessed using a chi-squared test 
or logistic regression for categorical variables and an ANOVA for 
continuous variables. With an alpha error of 5%, statistical sig-
nificance for all analyses was assumed with P < .05 (2-tailed). 
Survival analysis was conducted to be able to use all patient 
data including right-censored cases due to dropout events. It 
was assumed that treatment response did not differ between 
patients remaining in the study until remission and dropout. 
Median survival times were calculated using Kaplan-Meier sta-
tistics. Differences in time to remission were analyzed using Cox 
Regression Modeling. Model comparison was based on the likeli-
hood ratio test (LRS). Of primary interest was an overall differ-
ence between groups. This was evaluated using the likelihood 
ratio test. All other comparisons were performed exploratively 
and thus no type I error adjustment was performed.
Results
Of 593 patients who entered the naturalistic study (Seemuller 
et al., 2010) between 2000 and 2005, 475 (80.1%) enrolled in GAP3 
at 10 sites (see Acknowledgments). Of these 475 patients, 429 
were eligible for further analysis (Figure  2). Table  1 shows the 
baseline characteristics of the study sample.
Time to Remission
Cox regression survival analysis showed a significant difference 
in median time to remission between groups (42 [95% CI 30.95–
53.05] days for ALGO LA, 37 [Cl 28.36–45.64] days for ALGO DE, 40 
[95% Cl 29.21–50.79] days for ALGO SW, 45 [95% Cl 32.74–57.25] 
days for CDES vs 45 [95% Cl 32.09–57.91] days for TAU, likelihood 
ratio test = 11.078, P = .026). Compared with TAU, subsequent Cox 
regression analysis showed that the probability for remission 
was significantly higher for ALGO DE (HR = 1.67 [95%CI 1.11–2.52] 
Wald test = 6.03, P = .014) and for ALGO SW (HR = 1.64 [95%CI 
1.10–2.48] Wald test = 5.60, P = .018), but narrowly missed statis-
tical significance for ALGO LA (HR = 1.49 [95%CI 0.99–2.25] Wald 
test = 3.69, P = .055), while there was no difference for time to 
remission between CDES and TAU (HR = 1.06 [95% CI 0.68–1.63], 
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Wald test = 0.06, P = .811) (HR = 1.06 [95% CI 0.68–1.63], Wald 
test = 0.06, P = .811). Compared with CDES, probability for remis-
sion was significantly higher for ALGO DE (HR = 1.59 [95% CI 1.04–
2.41] Wald test = 4.64, P = .031), for ALGO SW (HR = 1.56 [95%CI 
1.03–2.37] Wald = 4.30, P = .038), but not for ALGO LA (HR = 1.42 
[95%CI 0.93–2.15] Wald test = 2.66, P = .103) (Figure 3).
Remission and Dropout Analysis
Of 429 patients, 235 (54.8%) achieved remission and 276 (64.3%) 
achieved response during the study (reduction of HAMD-21 score 
≥50%). Remission or response rates during the study and time in 
hospital were not different between the 5 groups (Table 2).
Overall, 169/429 (39.4%) dropped out of the study protocol 
for various reasons (see supplementary Table 1). Dropouts were 
less frequent in TAU (19%) than in each of the 3 ALGO pathways: 
ALGO LA (40.7%), ALGO DE (42.9%), ALGO SW (42.7%), as well as 
CDES (50.6%) (chi-square = 19.70; P = .001).
Figure  2 provides an overview of remission and dropout 
rates per step or per week. Within ALGO, most of the remissions 
(45.1% of the intention-to-treat [ITT] sample, 77.9% of remitted 
patients) and most of the dropouts (36.1% of ITT sample, 85.7% 
of dropouts) occurred during the first (antidepressive mono-
therapy) step. In the second and third steps, another 9.8% and 
3%, respectively, of the initial sample achieved remission. In 
CDES, most of the remissions (64.1% of remitted patients, 31.6% 
of ITT sample) and of dropouts (57.5% of dropouts, 29.1% of ITT 
sample) occurred during the first 4 weeks of treatment. In TAU, 
50% of final remitters remitted during the first 4 weeks of treat-
ment (25% of ITT sample).
Status at Discharge
At hospital discharge, HAMD-21 data were available for 318/429 
(74.1%) of participants of whom 245/318 (77%) were remitted. 
A  total of 76.6% of patients from the ALGO LA pathway were 
remitted compared with 89.2% of patients from ALGO DE, 85.5% 
from ALGO SW, 67.7% from CDES, and 66.2% from TAU (chi-
square = 15.36, P = .004).
Treatment Features
Complete medication data were available for 350 patients. The 
subgroup analysis of those patients who achieved remission 
(n = 217) showed that patients in ALGO LA and ALGO DE needed 
fewer different kinds of antidepressants than patients in either 
CDES or TAU (Table 3), even when taking into account time to 
remission in an ANCOVA.
Of remitters, (n = 217) 46.5% received hypnotics. CDES 
patients were more likely to be prescribed hypnotics than TAU 
patients (OR = 3.95 [95 % CI 1.51–10.34], P = .005), but not patients 
in the ALGO pathways (Table 3).
Until remission, 12% of the patients (26/217) were treated 
with antidepressant doses below the minimal effective dose in 
Figure 2. Overview of remission and dropouts in the study groups and throughout the ALGO pathways. AD mono, antidepressant monotherapy; ALGO, standardized 
stepwise drug treatment algorithm; ALGO DE, ALGO pathway with dose escalation; ALGO LA, ALGO pathway with lithium augmentation; ALGO SW, ALGO pathway 
with antidepressant switch; CDES, computerized documentation and expert system; GAP3, German Algorithm Project phase 3; MAOI, monoamine oxidase inhibitor; 
T3, trijodthyronine; TAU, treatment as usual.
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at least one of the prescribed antidepressants. The risk of being 
treated with insufficiently dosed antidepressants was signifi-
cantly higher in CDES than TAU (OR = 6.00 [95% CI 1.18–30.53], 
P = .031), whereas patients in the 3 ALGO pathways were at sig-
nificantly lower risk compared with CDES (ALGO LA (OR = 0.15 
[95% CI 0.03–0.75], P = .021), in ALGO DE (OR = 0.144 [95% CI 0.03–
0.73], P = .019), and in ALGO SW (OR = 0.14 [95% CI 0.03–0.70], 
P = .017). There was no significant difference between ALGO 
groups and TAU.
Discussion
Study results indicated that algorithm-guided treatment of 
depression (ALGO) is generally associated with a shorter time to 
Table 1. Baseline Characteristics of Study Sample
ALGO LA ALGO DE ALGO SW CDES TAU Statistic P
Sample size 86 91 89 79 84
Female (%)
n = 428
65.9 62.6 62.9 74.7 51.2 Chi2 = 9.978 .041
Age (years: M, sd)
n = 429
45.6 ± 11.1 44.3 ± 13.3 42.2 ± 13.4 43.6 ± 12.5 45.1 ± 11.7 F = 1.012 .401
Married / partnership 
(%)
n = 397
45.0 34.9 44.6 38.9 38.2 Chi2 = 2.619 .623
Number of children 
(M, sd)
n = 356
1.3 ± 1.1 1.1 ± 1.3 1.1 ± 1.1 1.0 ± 1.0 1.1 ± 1.1 F = 0.724 .576
Employed (full- or 
part-time) (%)
n = 385
45.1 32.1 55.7 33.8 36.1 Chi2 = 12.526 .014
High school diploma 
(%)
n = 389
















10.7 5.6 8.0 5.2 3.7 Chi2 = 4.117 .390




25.9 ± 6.5 25.4 ± 5.3 25.4 ± 5.8 25.6 ± 6.0 27.4 ± 6.3 F = 1.668 .156




20.8 ± 31.3 13.6 ± 15.4 15.9 ± 14.8 29.5 ± 73.7 18.6 ± 24.7 F = 1.280 .278
Duration since illness 
onset (years; M, SD)
n = 262






2.3 ± 2.1 2.7 ± 2.9 1.8 ± 1.4 2.4 ± 1.7 2.8 ± 2.4 F = 1.660 .160
Comorbidity
 Psychiatric (%) n = 420 27.1 24.7 20.7 22.1 24.4 Chi2 = 1.145 .887
 Personality disorder (%) 
n = 429
5.8 12.1 10.1 8.9 8.3 Chi2 = 2.282 .684
ALGO: standardized stepwise drug treatment algorithm; ALGO LA: ALGO pathway with lithium augmentation; ALGO DE: ALGO pathway with dose escalation; ALGO 
SW: ALGO pathway with antidepressant switch; HAMD: Hamilton Rating Scale for Depression; BDI: Beck Depression Inventory; CDES: computerized documentation 
and expert system, TAU: treatment as usual.
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remission than either an individualized CDES or TAU. Probability 
of achieving remission was significantly higher for ALGO DE and 
ALGO SW but narrowly failed statistical significance for ALGO 
LA. Dropout rates are relatively high in all 3 ALGO pathways and 
less frequent in TAU. ALGO-treated patients who dropped out of 
the protocol still maintained a higher probability of leaving the 
hospital in remission than patients in CDES or TAU, although 
durations of inpatient treatment did not differ between the 
groups.
We found more insufficient dosing of antidepressants and 
prescription of hypnotics in CDES and higher numbers of anti-
depressants used to achieve remission in TAU and CDES groups 
than for either ALGO LA or ALGO DE pathways.
These findings are in line with our single site GAP2 project 
(Bauer et  al., 2009), which demonstrated superior clinical out-
comes of a similar standardized step-wise treatment algorithm 
compared with TAU. In contrast, however, the present study 
did not find that any of the ALGO pathways were associated 
with fewer strategy changes or less polypharmacy than TAU to 
achieve remission.
The efficacy of algorithm-guided depression treatments has 
been shown in several smaller studies and large-scale multi-site 
projects in different outpatient settings. The Texas Medication 
Algorithm Project found a superior overall treatment outcome 
and fewer side effects for patients being treated with a guided 
medication treatment algorithm (Trivedi et  al., 2004). A  more 
recent Japanese study reported a 10% higher remission rate 
for algorithm-treated patients following a stepwise treatment 
procedure compared with TAU (Yoshino et  al., 2009). A  recent 
randomized controlled study from China showed that meas-
urement-based care, that is, the use of a symptom-rating scale, 
together with a dosing schedule showed superior outcomes 
compared with TAU even if medication and dose ranges did not 
differ between groups (Guo et al., 2015). Controlled studies and 
open trials in geriatric populations also showed the feasibility 
and effectiveness of intensive managed care programs (Flint 
and Rifat, 1996; Hawley et al., 1998; Mulsant et al., 2001; Unutzer 
et  al., 2002; Bruce et  al., 2004; Alexopoulos et  al., 2005). The 
Sequenced Treatment Alternatives to Relieve Depression study 
evaluated a measurement-based, stepwise treatment approach 
in a large outpatient sample with nonpsychotic MDD (Rush 
et  al., 2006; Trivedi et  al., 2006a). However, the study failed to 
show the superiority of any of the compared escalation strate-
gies (different augmentation, combination, or switch strategies) 
in nonresponders.
Notably, in this study, only a highly schematized algorithm-
guided procedure resulted in superior outcomes but not an 
individualized software-based treatment assistance. This find-
ing supports a major theory in algorithm research that diligent 
treatment management with a highly structured measurement-
based procedure accounts for the difference in treatment out-
comes rather than the application of a particular treatment 
Figure 3. Time to remission for standardized stepwise drug treatment algorithm (ALGO) pathway with lithium augmentation (ALGO LA), ALGO pathway with dose 
escalation (ALGO DE), ALGO pathway with antidepressant switch (ALGO SW), computerized documentation and expert system (CDES), and treatment as usual (TAU).
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strategy per se (Adli et al., 2006; Rush, 2015). A more individu-
alized treatment guidance that lacks clear-cut treatment strat-
egies and without explicit “if-then” rules is not different from 
TAU and, therefore, might not be cost effective. In contrast, we 
even found a higher rate of insufficiently dosed antidepressants 
in CDES, which might also explain the lower remission and 
response rates in this group compared with ALGO (Rush, 2015). 
This finding shows that algorithms also bear the risk of decre-
menting treatment processes.
Our results show a shorter time to remission for ALGO DE 
and ALGO SW but only a nonsignificant trend for ALGO LA com-
pared with CDES and TAU. We had expected lithium augmen-
tation to prove more effective than dose escalation or switch 
of antidepressant with regard to the broad basis of evidence in 
favor of this strategy (Crossley and Bauer, 2007). However, inter-
pretation of our second step results has to be done with caution 
due to the low number of patients in this study step and insuf-
ficient statistical power.
Future studies need to address the question of the appropri-
ate timing of CDPs and different response categories that result 
in specific operational consequences in a specific clinical envi-
ronment (outpatients, inpatients, characteristics of health sys-
tem). The question of which treatment sequences are preferred 
for particular subpopulations (e.g., stage of treatment resistance, 
age, presence of psychiatric and nonpsychiatric comorbidities) 
needs clarification. Before implementation into clinical practice, 
algorithm developers must ensure feasibility and clinical effi-
cacy of a treatment algorithm in a particular treatment environ-
ment and applicability to patient subgroups, as demonstrated 
by our CDES results.
Study limitations include: the lack of power in all 3 algo-
rithm-guided treatment steps after step one, primarily due to 
a high remission rate during antidepressant monotherapy. In 
addition, the study team, clinical staff, and patients were not 
masked to treatment assignment, which could have led to a bias 
in favor of the ALGO groups. However, response assessments 
were performed by staff that was not involved in the treatment 
of the patient. A  conservative bias results from the fact that 
the same clinicians who treated ALGO and CDES patients also 
treated patients in TAU, which is expected to result in “contami-
nation” of TAU with ALGO and CDES treatment procedures, thus 
reducing outcome differences between the groups. Also, differ-
ences in distribution of clinical or sociodemographic variables 
between the treatment groups (such as gender, type of depres-
sion [single vs recurrent], duration of the illness, or percent-
age of psychotic depression) could be of clinical relevance and 
therefore may weaken the interpretation of our results. As the 
dropout rate in TAU is lower than ALGO or CDES while 2 of the 
Table 2. Remission and Responsea
ALGO LA ALGO DE ALGO AS CDES TAU statistic P
Remission (n, %) 51 (59.3) 52 (57.1) 51 (57.3) 39 (49.4) 42 (50) chi2 = 2.853 .583
Response (n, %) 54 (62.8) 57 (62.6) 59 (66.3) 45 (57) 61 (72.6) chi2 = 4.736 .315
Total time in hospital (d)
Completer (M, SD) 50.5 (28.6) 53.4 (25.3) 55.9 (34.3) 49.3 (26.1) 52.4 (29.7) F = 0.183 .833
Total sample (M, SD) 53.6 (37.1) 55.6 (34.1) 55.4 (42.2) 58.6 (45.6) 50.6 (32.5) F = 0.363 .835
Abbreviaitons: ALGO, standardized stepwise drug treatment algorithm; ALGO DE, ALGO pathway with dose escalation; ALGO LA, ALGO pathway with lithium aug-
mentation; ALGO SW, ALGO pathway with antidepressant switch; CDES, computerized documentation and expert system; TAU, treatment as usual.
aRemission (HAMD-21≤9), response (reduction of HAMD-21 score ≥50%) during study duration and time in hospital for ALGO.
Table 3. Characteristics of Pharmacological Treatment
ALGO LA ALGO DE ALGO AS CDES TAU
M (SD) M (SD) M (SD) M (SD) M (SD) F P
Number of antidepressants 1.00 (0.00) 1.00 (0.00) 1.22 (0.42) 1.29 (0.58) 1.29 (0.46) 7.21 .000
Defined daily doses (DDD) of 
antidepressants
61.09 (42.03) 69.62 (59.85) 57.94 (36.73) 61.59 (59.06) 80.15 (71.51) 1.16 .329
Treatment duration with 1st 
antidepressant (d)
31.22 (18.36) 31.40 (18.72) 27.41 (11.99) 31.26 (19.84) 34.21 (20.85) 0.83 .510
Number of different pharmacological drug 
classes
2.54 (1.09) 2.57 (1.14) 2.47 (0.92) 2.76 (1.02) 2.44 (1.18) 0.53 .716
Number of strategy changes 1.59 (0.88) 1.68 (1.09) 1.98 (1.55) 1.97 (1.57) 2.20 (1.75) 1.38 .241
Number of hypnotics 0.72 (1.07) 0.62 (0.82) 0.59 (0.79) 0.76 (0.65) 0.41 (0.67) 1.07 .372
Defined daily doses (DDD) of hypnotics 8.31 (17.26) 9.04 (14.92) 16.45 (53.83) 11.11 (18.06) 7.49 (18.36) 0.69 .599
Treatment duration with hypnotics (d) 7.70 (12.03) 8.96 (14.06) 10.12 (18.74) 11.56 (16.89) 6.95 (14.49) 0.56 .689
Number of tranquilizer 0.63 (0.57) 0.60 (0.54) 0.67 (0.47) 0.74 (0.57) 0.56 (0.55) 0.61 .653
Defined daily doses (DDD) of tranquilizer 4.41 (7.55) 7.98 (15.16) 9.41 (15.89) 6.92 (12.05) 9.64 (19.16) 0.97 .423
Treatment duration with tranquilizer (d) 7.20 (10.92) 8.91 (14.06) 11.14 (16.13) 9.29 (14.26) 9.32 (14.89) 0.47 .760
Number of Antipsychotics 0.28 (0.72) 0.49 (0.83) 0.37 (0.67) 0.35 (0.65) 0.27 (0.67) 0.69 .601
Defined daily doses (DDD) of 
antipsychotics
3.20 (10.35) 8.35 (19.05) 5.08 (15.68) 4.12 (11.94) 6.15 (25.42) 0.59 .669
Treatment duration with antipsychotics (d) 4.46 (11.98) 8.93 (16.42) 4.88 (11.99) 4.53 (11.22) 7.29 (23.03) 0.74 .563
Abbreviations: ALGO, standardized stepwise drug treatment algorithm; ALGO AS, ALGO pathway with antidepressant switch; ALGO DE, ALGO pathway with dose 
escalation; ALGO LA, ALGO pathway with lithium augmentation; CDES, computerized documentation and expert system; TAU, treatment as usual.
DDD is the assumed average maintenance dose per day for a drug used for its main indication in adults; each new prescription and each discontinuation was con-
sidered a strategy change.
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ALGO groups did better in terms of time to remission, it cannot 
be ruled out that subjects doing poorly in ALGO or CDES dropped 
out whereas they stayed in the TAU group. However, as survival 
analysis regards dropouts as treatment failures such a bias 
seems unlikely to have influenced the result. Results are appli-
cable only to inpatient populations. Inpatient stays in Germany 
are longer in average compared with the United States, which 
might limit generalizability. However, the German healthcare 
system has a relatively low threshold for hospital admission 
of depressed patients, so results would seem to be generaliz-
able to the more severely ill depressed patients regardless of 
treatment venue.
In summary, these results demonstrate that an algorithm-
guided treatment procedure that entails the regular measure-
ment of outcomes and mandates next steps results in a higher 
probability of achieving remission and of leaving the hospital in 
remission than TAU. ALGO reduces the number of antidepres-
sant compounds needed to achieve remission. In contrast, we 
showed that algorithms may also bear risks, as seen with CDES 
with its less clear recommendations, and therefore need to be 
evaluated before implementing them in clinical practice.
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